OppenheimerFunds Inc. lifted its stake in Omnicell, Inc. (NASDAQ:OMCL) by 40.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 440,006 shares of the company’s stock after buying an additional 126,437 shares during the period. OppenheimerFunds Inc. owned about 1.07% of Omnicell worth $35,569,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in OMCL. BlackRock Inc. lifted its stake in Omnicell by 2.7% during the first quarter. BlackRock Inc. now owns 6,068,905 shares of the company’s stock worth $490,611,000 after purchasing an additional 162,222 shares during the period. Conestoga Capital Advisors LLC lifted its stake in Omnicell by 1.0% during the first quarter. Conestoga Capital Advisors LLC now owns 1,546,168 shares of the company’s stock worth $124,992,000 after purchasing an additional 15,353 shares during the period. Carillon Tower Advisers Inc. lifted its stake in Omnicell by 24.0% during the first quarter. Carillon Tower Advisers Inc. now owns 620,512 shares of the company’s stock worth $50,162,000 after purchasing an additional 120,109 shares during the period. Principal Financial Group Inc. lifted its stake in Omnicell by 0.6% during the first quarter. Principal Financial Group Inc. now owns 492,103 shares of the company’s stock worth $39,781,000 after purchasing an additional 2,889 shares during the period. Finally, Geode Capital Management LLC lifted its stake in Omnicell by 7.9% during the fourth quarter. Geode Capital Management LLC now owns 442,184 shares of the company’s stock worth $27,079,000 after purchasing an additional 32,512 shares during the period. Institutional investors and hedge funds own 97.32% of the company’s stock.
Shares of NASDAQ OMCL traded down $0.07 during mid-day trading on Wednesday, hitting $83.45. 5,227 shares of the stock were exchanged, compared to its average volume of 322,136. The firm has a market cap of $3.44 billion, a price-to-earnings ratio of 54.53, a PEG ratio of 2.60 and a beta of 1.14. The company has a current ratio of 1.96, a quick ratio of 1.47 and a debt-to-equity ratio of 0.13. Omnicell, Inc. has a twelve month low of $49.45 and a twelve month high of $86.87.
Omnicell (NASDAQ:OMCL) last posted its quarterly earnings data on Thursday, April 25th. The company reported $0.61 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.23 by $0.38. The company had revenue of $202.50 million during the quarter, compared to analyst estimates of $199.72 million. Omnicell had a net margin of 4.74% and a return on equity of 11.10%. The company’s revenue was up 10.9% on a year-over-year basis. During the same quarter last year, the business posted $0.29 earnings per share. On average, analysts forecast that Omnicell, Inc. will post 2.06 earnings per share for the current year.
OMCL has been the subject of a number of analyst reports. Zacks Investment Research cut shares of Omnicell from a “hold” rating to a “sell” rating in a research note on Friday, February 15th. Benchmark raised their price target on shares of Omnicell from $82.00 to $90.00 and gave the stock a “buy” rating in a research note on Friday, April 26th. BidaskClub cut shares of Omnicell from a “hold” rating to a “sell” rating in a research note on Tuesday, April 23rd. Dougherty & Co raised their price target on shares of Omnicell from $78.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, March 7th. Finally, ValuEngine raised shares of Omnicell from a “buy” rating to a “strong-buy” rating in a report on Friday, March 1st. Five investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Omnicell presently has a consensus rating of “Buy” and a consensus price target of $79.89.
In other news, Chairman Randall A. Lipps sold 65,161 shares of the firm’s stock in a transaction that occurred on Monday, April 29th. The shares were sold at an average price of $63.77, for a total transaction of $4,155,316.97. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Nhat H. Ngo sold 1,823 shares of the firm’s stock in a transaction that occurred on Thursday, March 21st. The shares were sold at an average price of $82.33, for a total transaction of $150,087.59. Following the completion of the sale, the executive vice president now directly owns 37,569 shares of the company’s stock, valued at approximately $3,093,055.77. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 131,224 shares of company stock valued at $9,469,511. Company insiders own 2.77% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece of content was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2019/06/12/oppenheimerfunds-inc-grows-position-in-omnicell-inc-nasdaqomcl.html.
Omnicell Company Profile
Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.
Featured Story: What can cause a stock to outperform?
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.